E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives of this study are: • To assess the efficacy of CNS-242, after 8 weeks’ treatment, in reducing SUA as a surrogate marker of gout (reduction of SUA to a level of 6 mg/dL). • To assess the safety and tolerability of multiple doses of CNS-242 in patients with previous gout attacks and hyperuricaemia.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are: • To assess the change from baseline in SUA after 8 weeks’ treatment with CNS-242. • To determine and compare the number of patients experiencing acute attacks of gout during 8 weeks’ treatment with CNS-242. • To determine any reduction in tophi after 8 weeks’ treatment with CNS-242. • To determine any reduction in levels of pain during and after 8 weeks’ treatment with CNS 242. • To assess patient quality of life during and after 8 weeks’ treatment with CNS-242.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
To be eligible for inclusion into the study, each patient must fulfil all of the following criteria:
1. Adults aged at least 18 years. 2. Patients with pharmacologically controlled gout, defined as: • at least one previous documented clinical diagnosis of an attack, but no attack in the 6 months prior to screening, of acute arthritis of the first metatarsal phalangeal joint of the big toe, tenderness and swelling 3. Levels of SUA ≤ 8 mg/dL at the screening visit, prior to the start of the wash out period. All other clinical laboratory tests within normal ranges and acceptable to the investigator. 4. Patients under a stable anti-hyperuricaemic treatment with allopurinol, probenecid or sulfinpyrazone in the month before screening. 5. Willing and able to give written informed consent prior to any study-specific screening procedures and comply with the study protocol for the duration of the study.
|
|
E.4 | Principal exclusion criteria |
Patients are not eligible for this study if they fulfil one or more of the following conditions:
1. Patients who are pregnant or breast-feeding. Women of child-bearing potential must be willing and able to use an adequate method of contraception during the course of the study and must have a negative pregnancy test prior to receiving study drug. 2. Acute gout attack in the 6 months before screening. 3. Use of colchicine in the month prior to screening. Patients meeting this criterion at the screening visit can re-attend for a second screening visit. 4. Use of NSAIDs within 2 weeks of screening. Patients meeting this criterion at the screening visit can re-attend for a second screening visit. 5. Have a clinically relevant history or presence of gastrointestinal, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological or connective tissue diseases or disorders, including hepatic insufficiency (transaminases > 5 x upper limit of normal) and renal insufficiency (CrCl < 30 ml/min) which, in the opinion of the investigator, makes the patient unsuitable for the study. 6. Have a clinically relevant ECG abnormality. 7. Have congestive heart failure, New York Heart Association class III and IV. 8. Have any malignancies in the previous 5 years, with the exception of basal cell carcinoma (excised). 9. Have a clinically relevant surgical history. 10. Have a history of alcoholism or drug abuse. 11. Have used any investigational drug and/or participated in any clinical trial within 3 months of their first admission to this study. 12. Have previously received CNS-242. 13. Patients who, in the opinion of the investigator, are not able to comply with the protocol, are poor medical candidates or pose a psychiatric risk for therapy with an investigational drug. 14. Unwilling or unable to give written informed consent.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The efficacy analysis population will be used for the primary analysis of the primary endpoint.
The primary endpoint is the proportion of patients with a reduction of SUA to a level of 6 mg/dL or below. It is considered that if more than 50% of patients in either dose group achieve SUA ≤ 6 mg/dL after 8 weeks’ treatment this will be indicative of a pharmacological effect in an accepted surrogate marker for gout, and worth exploring in a more formal dose finding study. Therefore the efficacy of CNS-242 will be examined via null hypotheses for each dose of the form.
H0; The proportion of subjects in the CNS-242 dose group with SUA ≤ 6 mg/dL at Visit 5 is < 50%. HA; The proportion of subjects in the CNS-242 dose group with SUA ≤ 6 mg/dL at Visit 5 is ≥ 50%.
The proportion of patients with reduction of SUA to a level of 6 mg/dL or below (successes) will be summarised using tables of frequencies and other descriptive statistics. The null hypothesis will be tested by calculating the exact two-sided probability of the actual proportion of successes, given a binomial distribution with expected proportion of 50%.
Patients not experiencing an initial increase in SUA to levels above 7 mg/dL (from Visit 1 to Visit 2) will be excluded from the above primary analyses of the primary endpoint.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 8 |